MX2013007502A - Solucion oftalmica que comprende diquafosol, metodo para producir la misma, y metodo para inhibir la formacion de precipitado insoluble. - Google Patents

Solucion oftalmica que comprende diquafosol, metodo para producir la misma, y metodo para inhibir la formacion de precipitado insoluble.

Info

Publication number
MX2013007502A
MX2013007502A MX2013007502A MX2013007502A MX2013007502A MX 2013007502 A MX2013007502 A MX 2013007502A MX 2013007502 A MX2013007502 A MX 2013007502A MX 2013007502 A MX2013007502 A MX 2013007502A MX 2013007502 A MX2013007502 A MX 2013007502A
Authority
MX
Mexico
Prior art keywords
ophthalmic solution
solution containing
containing diquafosol
insoluble precipitate
formation
Prior art date
Application number
MX2013007502A
Other languages
English (en)
Inventor
Akiko Sakatani
Tatsuo Ikei
Koji Nagaki
Masaki Sonoda
Yoko Fukui
Mitsuaki Kuwano
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of MX2013007502A publication Critical patent/MX2013007502A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Con respecto a solución oftálmica de Diquafosol que comprende un agente quelante, se ha inhibido la formación de precipitados insolubles encontrada en solución oftálmica de Diquafosol durante su almacenamiento, así como el deterioro del desempeño en filtración en el curso de producción (esterilización por filtración). Además, en la solución oftálmica de Diquafosol que comprende un agente quelante, se ha confirmado la mejora de la eficacia conservadora. En consecuencia, la presente invención proporciona UNA solución oftálmica de Diquafosol que tiene propiedades fisioquímicas que son estables durante los cursos de producción y distribución así como el curso de almacenamiento por un paciente. Particularmente en el curso de producción, la solución se puede someter a esterilización por filtración eficiente. Por otra parte, la solución tiene excelente eficacia conservadora. La presente invención también proporciona un método para inhibir la formación de precipitados insoluble de una solución oftálmica acuosa que comprende diquafosol o una sal de los mismos, al agregar un agente quelante a la solución.
MX2013007502A 2010-12-28 2011-12-27 Solucion oftalmica que comprende diquafosol, metodo para producir la misma, y metodo para inhibir la formacion de precipitado insoluble. MX2013007502A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010291463 2010-12-28
PCT/JP2011/080179 WO2012090994A1 (ja) 2010-12-28 2011-12-27 ジクアホソル含有点眼液およびその製造方法、不溶性析出物発生の抑制方法

Publications (1)

Publication Number Publication Date
MX2013007502A true MX2013007502A (es) 2013-08-01

Family

ID=46383087

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007502A MX2013007502A (es) 2010-12-28 2011-12-27 Solucion oftalmica que comprende diquafosol, metodo para producir la misma, y metodo para inhibir la formacion de precipitado insoluble.

Country Status (16)

Country Link
US (1) US20140221306A1 (es)
EP (1) EP2659894A4 (es)
JP (1) JP2012149057A (es)
KR (1) KR20140003493A (es)
CN (1) CN103282039A (es)
AU (1) AU2011350762B2 (es)
BR (1) BR112013016008B1 (es)
CA (1) CA2823148A1 (es)
EA (1) EA027736B1 (es)
GE (1) GEP20166448B (es)
MX (1) MX2013007502A (es)
MY (1) MY161032A (es)
SG (2) SG10201508591UA (es)
TW (1) TW201306844A (es)
UA (1) UA113839C2 (es)
WO (1) WO2012090994A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071113B2 (en) 2012-03-26 2018-09-11 Santen Pharmaceutical Co., Ltd. Ophthalmic solution comprising diquafosol

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017013841A2 (pt) * 2014-12-25 2018-06-19 Santen Pharmaceutical Co., Ltd. solução oftálmica aquosa
TW201707710A (zh) 2015-06-05 2017-03-01 參天製藥股份有限公司 特徵爲用於滴入戴著軟性隱形眼鏡的乾眼症患者的眼睛之乾眼症治療劑
EA202092030A1 (ru) * 2018-02-28 2020-11-16 Сантен Фармасьютикал Ко., Лтд. Офтальмологическая композиция, включающая диквафозол и катионный полимер
CN108853016A (zh) * 2018-09-26 2018-11-23 广州大光制药有限公司 一种地夸磷索钠滴眼液及其制备方法
CN113518646B (zh) * 2019-02-27 2023-12-12 参天制药株式会社 含有地夸磷索或其盐，乙烯基系高分子及纤维素系高分子的眼科用组合物
CN117771172A (zh) * 2019-08-27 2024-03-29 参天制药株式会社 含有地夸磷索或其盐、及聚乙烯吡咯烷酮的水性眼科用组合物
JP7230169B2 (ja) * 2020-12-25 2023-02-28 参天製薬株式会社 ジクアホソルまたはその塩、銀塩およびイオン性等張化剤を含有する水性点眼液
CN113712910A (zh) * 2021-08-05 2021-11-30 广州市桐晖药业有限公司 一种滴眼液及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
CA2295515C (en) 1997-07-25 2006-03-14 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5'-tetraphosphate) and salts thereof
JP4003008B2 (ja) * 2000-05-30 2007-11-07 参天製薬株式会社 角膜上皮伸展促進剤
AU2001260643B9 (en) * 2000-05-30 2006-10-19 Merck Sharp & Dohme Corp. Ectocornea extension promoters
JP2003160491A (ja) * 2001-09-11 2003-06-03 Santen Pharmaceut Co Ltd ジウリジンリン酸含有点眼液
JP4168071B2 (ja) 2005-12-08 2008-10-22 興和株式会社 点眼用組成物
CN103096929A (zh) * 2010-09-10 2013-05-08 参天制药株式会社 以组合p2y2受体激动剂和透明质酸或其盐为特征的干眼症治疗剂、干眼症的治疗方法、及干眼症治疗剂的应用

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071113B2 (en) 2012-03-26 2018-09-11 Santen Pharmaceutical Co., Ltd. Ophthalmic solution comprising diquafosol
US10632139B2 (en) 2012-03-26 2020-04-28 Santen Pharmaceutical Co., Ltd. Ophthalmic solution comprising diquafosol
US11166974B2 (en) 2012-03-26 2021-11-09 Santen Pharmaceutical Co., Ltd. Ophthalmic solution comprising Diquafosol

Also Published As

Publication number Publication date
SG191389A1 (en) 2013-07-31
MY161032A (en) 2017-04-03
KR20140003493A (ko) 2014-01-09
BR112013016008A2 (pt) 2018-07-10
SG10201508591UA (en) 2015-11-27
CN103282039A (zh) 2013-09-04
EP2659894A1 (en) 2013-11-06
CA2823148A1 (en) 2012-07-05
GEP20166448B (en) 2016-03-25
UA113839C2 (xx) 2017-03-27
WO2012090994A1 (ja) 2012-07-05
AU2011350762B2 (en) 2017-04-06
BR112013016008B1 (pt) 2021-06-29
JP2012149057A (ja) 2012-08-09
EP2659894A4 (en) 2014-12-10
EA027736B1 (ru) 2017-08-31
EA201390985A1 (ru) 2013-11-29
AU2011350762A1 (en) 2013-07-25
US20140221306A1 (en) 2014-08-07
TW201306844A (zh) 2013-02-16

Similar Documents

Publication Publication Date Title
MX2013007502A (es) Solucion oftalmica que comprende diquafosol, metodo para producir la misma, y metodo para inhibir la formacion de precipitado insoluble.
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
MY169816A (en) Ophthalmic solution comprising diquafosol
MX2015008697A (es) Tratamiento contra la degeneración macular relacionada con la edad.
IN2014KN00948A (es)
TN2012000401A1 (en) Heterocyclic compound
PH12015500561A1 (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
TN2013000434A1 (en) Novel imidazole derivatives useful for the treatment of arthritis
PH12014502396B1 (en) Nitrogenated heterocyclic compound
WO2012033789A3 (en) Treatment of diseases
MX2013011589A (es) Metodos y composiciones para tratar enfermedad de parkinson.
GB2499559A (en) Treating cough and tussive attacks
PH12015500702B1 (en) Dialysis a agent comprising acetic acid and acetate, and two-part dialysis agent using same
WO2013142038A3 (en) Compositions and methods for inhibition of cathepsins
MX2013009805A (es) Preparación de sales de guanidina bicíclica en un medio acuoso.
MY161887A (en) Process for the production of chlorine dioxide
AU2011208681A8 (en) Aqueous solution comprising 3 - quinuclidinones for the treatment of hyperproliferative, autoimmune and heart disease
NZ700356A (en) Pyrazole compounds as sglt1 inhibitors
MX2015016057A (es) Solucion estabilizada de acido hipocloroso y uso de la misma.
MX2009007265A (es) Sales, composiciones liquidas acuosas que cotienen sales de acido s-(+)-abscisico y metodos para su preparacion.
MX2014008247A (es) Calmangafodipir, una nueva entidad quimica, y otros complejos de metal mezclados, metodos de preparacion, composiciones y metodos de tratamiento.
SMT201300112B (it) Sale citrato di 9E-15-(2-pirrolidin-1-il-etossi)-7,12,25-triossa-19,21,24-triaza-tetracicloÄ18.3.1.1(2,5).1(14,18)Üesacos a-1(24),2,4,9,14,16,18(26),20,22-nonaene
MY160005A (en) 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
MX2012012978A (es) Metodo para producir pleurodesis.
UA111145C2 (uk) Фармацевтична композиція